Empliciti (elotuzumab) / AbbVie, BMS - LARVOL DELTA

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. (PubMed, Blood) - P1/2, P3 | "We conducted a secondary pooled analysis of the S0777 and S1211 SWOG studies of NDMM, which employed lenalidomide-dexamethasone (Rd) alone with or without bortezomib (VRd) and with or without elotuzumab (Elo-VRd). Given dexamethasone's many toxicities and unclear benefit in the era of modern treatment regimens, dexamethasone dose reduction during NDMM induction warrants further prospective study. NCT00644228, NCT01668719."

Journal • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Insomnia • Multiple Myeloma • Oncology • Sleep Disorder • Thrombocytopenia

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM). (PubMed, Expert Opin Biol Ther) - "We review mechanisms of action, efficacy, real-world effectiveness, and key aspects of the safety profiles of daratumumab, isatuximab, elotuzumab, and belantamab mafodotin in RRMM. mAb/ADC-based regimens remain key options in this setting, offering practical, effective, and tolerable approaches for real-world practice. Ongoing research will inform individualized treatment choices and rational sequencing of therapies, with a need for immune-based biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and bispecific antibodies to further improve outcomes for patients with RRMM."

IO biomarker • Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology

Galectin-9 as a glycan-modulating adjuvant to enhance Elotuzumab-mediated immunotherapy in multiple myeloma (AACR 2026) - "Collectively, these findings highlight Gal-9 as a promising combinatorial agent capable of enhancing SLAMF7 expression and amplifying Elotuzumab-induced cytotoxicity in MM. This study underscores the therapeutic potential of integrating glycan-targeting strategies with existing monoclonal antibody-based regimens to improve treatment efficacy and patient outcomes in multiple myeloma."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • LGALS9 • SLAMF7

Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis. (PubMed, Ann Med) - "Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution."

Adverse events • Journal • Retrospective data • Anorexia • Back Pain • Cataract • CNS Disorders • Cough • Dermatology • Diabetes • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Insomnia • Multiple Myeloma • Musculoskeletal Pain • Neutropenia • Oncology • Ophthalmology • Pain • Pneumonia • Pruritus • Respiratory Diseases • Sleep Disorder • Thrombocytopenia • SLAMF7

Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. (PubMed, World J Methodol) - "While great strides have been made in the treatment, much remains to be learned about long-term safety, efficacy, and potential resistance mechanisms to these treatments."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov) - P3 | N=381 | Not yet recruiting | Sponsor: Celgene

New P3 trial • Multiple Myeloma

KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov) - P3 | N=381 | Recruiting | Sponsor: Celgene | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov) - P3 | N=381 | Recruiting | Sponsor: Celgene | Trial completion date: Jun 2025 ➔ Nov 2025 | Trial primary completion date: Jun 2025 ➔ May 2022

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (ISPOR 2026) - "OBJECTIVES: This systematic literature review aimed to evaluate the comparative effectiveness, health-related quality of life (HRQL), treatment preferences, and economic burden associated with lenalidomide plus dexamethasone (Rd)-based triplet regimens in relapsed and/or refractory multiple myeloma (RRMM). This review followed the Cochrane Handbook and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO registration: CRD420251136008)...Across unique studies, carfilzomib-Rd (KRd) was evaluated most frequently (n = 17), followed by ixazomib-Rd (IRd) and daratumumab-Rd (DRd) (n = 13 each), bortezomib-Rd (VRd; n = 9), and elotuzumab-Rd (ERd; n = 5)... Real-world evidence indicates that IRd provides effectiveness comparable to other Rd-based triplet regimens while offering lower healthcare costs and fewer outpatient visits, supporting its value as a treatment option in routine practice for RRMM. As new comparative evidence..."

Clinical • HEOR • Real-world • Real-world evidence • Review • Hematological Malignancies • Multiple Myeloma

KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov) - P3 | N=381 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2026 ➔ Apr 2027 | Trial primary completion date: Sep 2026 ➔ Apr 2027

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=67 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Dec 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=67 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=21 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Apr 2019 ➔ May 2020 | Trial primary completion date: Apr 2019 ➔ May 2020

Trial completion date • Trial primary completion date • Multiple Myeloma

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=67 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Dec 2024 ➔ Nov 2025 | Trial primary completion date: Dec 2024 ➔ Nov 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=28 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | N=21 ➔ 28

Enrollment change • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=67 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Mar 2024 ➔ Jun 2024 | Trial primary completion date: Mar 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: Aug 2018 ➔ Jan 2019

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=67 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=21 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov) - P2 | N=56 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | N=28 ➔ 56 | Trial completion date: Jul 2020 ➔ Aug 2023 | Trial primary completion date: Jul 2020 ➔ Aug 2023

Enrollment change • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity. (PubMed, Int Immunopharmacol) - "While ELO alone has shown modest single agent activity, combination with immunomodulatory drugs (IMIDs), such as lenalidomide and pomalidomide (POM), has proven beneficial in treating MM. NK cells exposed to the TCSCTX or CTX+POM from MM cells potentiated NK cell cytotoxicity of MM cells and induced expression of PD-L1 and CD47 on MM cells. Dual targeting of PD-L1 and CD47 using anti-PD-1 and an anti-CD47 antibody significantly enhanced NK cytotoxicity and secretion of anti-tumour effector molecules, TNF-α and granzyme B. These findings support the addition of CTX to ELO-containing MM regimens and provide a rationale for combining POM with immune checkpoint blockade to maximise NK cytotoxicity against MM."

IO biomarker • Journal • Hematological Malignancies • Multiple Myeloma • Oncology • CD47 • GZMB • SLAMF7 • TNFA

M22-574: A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monotherapy Study) (clinicaltrialsregister.eu) - P2/3 | N=147 | Active, not recruiting | Sponsor: AbbVie Deutschland GmbH & Co. KG | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Hematological Malignancies • Multiple Myeloma • Oncology

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS. (PubMed, Front Immunol) - "Fifty-four drugs showed significant signals in primary analysis with the exception of acalabrutinib in the analysis restricted to 6,258 cases, including established high-risk agents and potential novel associations. Notably, we observed signals with four monoclonal antibodies (daratumumab, elotuzumab, epcoritamab, and isatuximab); isatuximab had no previous mentions in regulatory labels or published literature to our knowledge. Among established agents, natalizumab had the highest number of reports (n=1,848; ROR 40.7), and rituximab also showed a strong signal (n=1,296; ROR 41.8)...Median TTO for antineoplastic drugs (13.6 months; 95% CI: 11.5-15.9) was significantly shorter than for non-antineoplastic drugs (42.4 months; 95% CI: 39.7-44.1). These findings reinforce established and emerging PML reporting signals with immunomodulatory therapies and support heightened pharmacovigilance-particularly for novel monoclonal antibodies used in hematologic malignancies."

Journal • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Multiple Sclerosis • Non-Hodgkin’s Lymphoma • Oncology • Rare Diseases

The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines. (PubMed, Molecules) - "ADCC was assessed by flow cytometry using E (100 μg/mL), rituximab (R, 100 μg/mL), and their combination (E + R). The combination of E + R showed no significant synergy over monotherapies. In conclusion, elotuzumab induced significant ADCC in CLL cells, warranting further therapeutic evaluation."

IO biomarker • Journal • Preclinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • SLAMF7